CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FiercePharma
Original article

{"a":[{"_":"IntraBio's Aqneursa scores expansion, now the first treatment for rare ataxia","$":{"href":"/pharma/intrabio-scores-aqneursa-expansion-now-first-treatment-globally-rare-ataxia","hreflang":"en"}}]}

RegulatoryapprovedAqneursaPositive
AI Analysis

Summary

IntraBio's Aqneursa has received approval for a second indication and is now the first treatment globally indicated for rare ataxia, expanding the company's portfolio in rare neurological conditions.

Outcome Details

First treatment globally indicated for rare ataxia; second indication expansion

Importance:6/10
Sentiment:
0.80
rare diseaseneurologicalindication expansionregulatory approval
Related Companies

Read the original article

Published by FiercePharma on September 21, 2026 10:47 AM

Read Original